This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Another stock that insiders are active in here is
Sarepta Therapeutics (
SRPT), which is focused on the discovery and development of ribonucleic acid-based therapeutics for the treatment of rare and infectious diseases. Insiders are buying this stock into major strength, since shares are up sharply by 35% so far in 2013.
>>4 Stocks Under $10 to Trade for Breakouts
Sarepta Therapeutics has a market cap of $1.17 billion and an enterprise value of $973 million. This stock trades at a premium valuation, with a price-to-sales of 50.99 and a price-to-book of 12.40. Its estimated growth rate for this year is 36.6%, and for next year it's pegged at 12.6%. This is a cash-rich company, since the total cash position on its balance sheet is $156.18 million and its total debt is just $1.71 million.
A director just
bought 3,500 shares, or about $114,000 worth of stock, at $32.68 per share.
From a technical perspective, SRPT is currently trending above both its 50-day and 200-day moving averages, which is bullish. This stock just came out of a nasty downtrend that took the stock from $47.35 to its recent low of $29.71 a share. Shares of SRPT have now entered a near-term uptrend, with the stock rebounding off that low of $29.71 and moving back above its 50-day moving average at $33.06 a share. That move has started to push SRPT within range of triggering a near-term breakout trade.
If you're bullish on SRPT, then look for long-biased trades as long as this stock is trending above its 200-day at $32.62 or above more support at $32, and then once it breaks out above some near-term overhead resistance at $35.49 a share high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average volume of 1.71 million shares. If that breakout hits, then SRPT will set up to re-test or possibly take out its next major overhead resistance levels at $39.12 to $42 a share.